Nick Evans
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nick Evans has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
- Martin Kluckow
Department of Neonatology, Royal North Shore Hospital and University of Sydney, Sydney, Australia
1 shared publication
Latest Publications
- 11 January 2016
- Published by Wiley in Acta Paediatrica
- Vol. 105 (2) , 121-122
Towards rational use of inhaled Nitric Oxide in preterm babies
- 11 January 2016
- Published by Wiley in Acta Paediatrica
- Vol. 105 (2) , 121-122
Towards rational use of inhaled Nitric Oxide in preterm babies
- 25 August 2015
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 175 (2) , 289-290
Point of care ultrasound in the NICU—training, accreditation and ownership
- 25 August 2015
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 175 (2) , 289-290
Point of care ultrasound in the NICU—training, accreditation and ownership
- 1 August 2015
- Published by Elsevier in Seminars in Fetal and Neonatal Medicine
- Vol. 20 (4) , 272-277
Preterm patent ductus arteriosus: A continuing conundrum for the neonatologist?
- 1 August 2015
- Published by Elsevier in Seminars in Fetal and Neonatal Medicine
- Vol. 20 (4) , 272-277
Preterm patent ductus arteriosus: A continuing conundrum for the neonatologist?
- 12 September 2012
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 48 (9) , 753-758
Preterm patent ductus arteriosus: Should we treat it?
Debate about the importance of the preterm patent ductus arteriosus (PDA) remains unresolved. Ultrasound studies of PDA have suggested that the haemodynamic impact may be much earlier after birth than previously thought, but we still do not know when to treat a PDA. Studies that have tested symptomatic or pre‐symptomatic treatment are mainly historical and have not tested the effect of no treatment. Prophylactic treatment is the best studied regimen, but improvements in some short‐term outcomes do not translate to any difference in longer term outcomes. Neonatologists have been reluctant to engage in trials that test treatment against not treating at all or very rarely. Targeting treatment on the basis of the early post‐natal constrictive response of the duct is currently being tested as a possible strategy.
- 12 September 2012
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 48 (9) , 753-758
Preterm patent ductus arteriosus: Should we treat it?
Debate about the importance of the preterm patent ductus arteriosus (PDA) remains unresolved. Ultrasound studies of PDA have suggested that the haemodynamic impact may be much earlier after birth than previously thought, but we still do not know when to treat a PDA. Studies that have tested symptomatic or pre‐symptomatic treatment are mainly historical and have not tested the effect of no treatment. Prophylactic treatment is the best studied regimen, but improvements in some short‐term outcomes do not translate to any difference in longer term outcomes. Neonatologists have been reluctant to engage in trials that test treatment against not treating at all or very rarely. Targeting treatment on the basis of the early post‐natal constrictive response of the duct is currently being tested as a possible strategy.